ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the clinical patterns of nivolumab-induced cytokine release syndrome (CRS), and to provide a basis for diagnosis, treatment and prognosis.
methodsClinical reports of nivolumab-induced CRS before March 31, 2026 were collected, and clinical data were extracted for retrospective analysis.
resultsThirty-five patients were included, with a median age of 55 years (range 3, 86). The median time for the appearance of CRS was 54.5 days (range 0.2, 391) and the median number of cycles was 3 (range 1, 17). Fever (85.7%), hypotension (57.1%), tachycardia (42.9%), fatigue (25.7%), rash (25.7%) and impaired consciousness (25.7%) were the main symptoms of patients. Laboratory tests may reveal liver injury, renal injury, elevated C-reactive protein, elevated ferritin, and elevated interleukin-6. After discontinuing nivolumab and receiving treatment with glucocorticoids and tocilizumab, 71.4% of the patients showed improvement in symptoms and clinical markers, while 28.6% of the patients died.
conclusionNivolumab-induced CRS can lead to multi-organ functional impairment and even be fatal. During the administration of nivolumab, the possibility of CRS should be taken into consideration. Glucocorticoids and tocilizumab are widely utilized as primary therapeutic approaches for the management of CRS in clinical practice. However, given the limited available evidence and inherent clinical confounders, the standardized and optimal treatment strategy for nivolumab-induced CRS remains undefined and requires further exploration.
Indexed as
Identifiers
42821011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.